Literature DB >> 21586213

Development and validation of French version of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument.

Sangmee Bae1, Yannick Allanore, Baptiste Coustet, Paul Maranian, Dinesh Khanna.   

Abstract

OBJECTIVES: The UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument (UCLA-SCTCGIT) 2.0 was developed to assess systemic sclerosis (SSc) associated gastrointestinal tract (GIT) symptoms severity and its impact on patients' well-being. Our objective was to translate the UCLA-GIT 2.0 from English to French and to evaluate the reliability and validity of the French version.
METHODS: UCLA-GIT 2.0 was adapted into French using a formal forward-backward translation method and administered to 76 French speaking patients with SSc. The patients also completed the SF-36. We evaluated the internal consistency reliability and construct validity by exploring associations between the UCLA SCTC GIT 2.0 and SF-36 scales. Patients were also classified into two groups based on unintended weight loss within the past 6 months (≥5% vs. <5% of total body weight).
RESULTS: Participants were mostly white (90%), female (81%) and had limited SSc (50%). Mean score of the UCLA-GIT 2.0 scales were: 0.35 for faecal soilage, 0.44 for diarrhoea, 0.45 for emotional well-being, 0.48 for both constipation and social functioning, 0.52 for reflux, and 0.95 for distension/bloating. The instrument had acceptable reliability (defined as Cronbach alpha≥0.69) except for the diarrhoea scale (alpha=0.56). The majority of hypothesized correlations were of moderate magnitude (coefficient≥0.30) and were in the appropriate direction. Patients with ≥5% unintended weight loss had worse UCLA-GIT scores in all scales (p<0.05 for distention/bloating scale).
CONCLUSIONS: The French version of the UCLA-GIT 2.0 has acceptable psychometric properties and can be used in French speaking SSc patients.

Entities:  

Mesh:

Year:  2011        PMID: 21586213

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  7 in total

1.  The validity and reliability study of the University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract (UCLA SCTC GIT) 2.0 questionnaire for the Turkish society.

Authors:  Yaşar Murat Taş; Gözde Derviş Hakim; Pembe Keskinoğlu; Gökçe Kenar; Handan Yarkan; Berrin Zengin; Gerçek Can; Fatoş Önen; Nurullah Akkoç; Merih Birlik; Mesut Akarsu
Journal:  Turk J Gastroenterol       Date:  2019-03       Impact factor: 1.852

2.  Association between the -174 C/G polymorphism in the interleukin-6 (IL-6) gene and gastrointestinal involvement in patients with systemic sclerosis.

Authors:  Ana Zekovic; Misa Vreca; Vesna Spasovski; Marina Andjelkovic; Sonja Pavlovic; Nemanja Damjanov
Journal:  Clin Rheumatol       Date:  2018-06-08       Impact factor: 2.980

3.  Validation of Serbian version of UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument in 104 patients with systemic sclerosis.

Authors:  Ana Zekovic; Nemanja Damjanov
Journal:  Rheumatol Int       Date:  2017-03-07       Impact factor: 2.631

4.  Validation of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument 2.0 in English- and Chinese-speaking patients in a multi-ethnic Singapore systemic sclerosis cohort.

Authors:  Andrea Hsiu Ling Low; Xiaohui Xin; Weng Giap Law; Gim Gee Teng; Amelia Santosa; Anita Lim; Grace Chan; Swee Cheng Ng; Julian Thumboo
Journal:  Clin Rheumatol       Date:  2017-01-05       Impact factor: 2.980

Review 5.  Measuring response in the gastrointestinal tract in systemic sclerosis.

Authors:  Dinesh Khanna; Vivek Nagaraja; Heather Gladue; William Chey; Mark Pimentel; Tracy Frech
Journal:  Curr Opin Rheumatol       Date:  2013-11       Impact factor: 5.006

6.  Construct validity of the Patient-Reported Outcomes Measurement Information System gastrointestinal symptom scales in systemic sclerosis.

Authors:  Vivek Nagaraja; Ron D Hays; Puja P Khanna; Brennan M R Spiegel; Lin Chang; Gil Y Melmed; Roger Bolus; Dinesh Khanna
Journal:  Arthritis Care Res (Hoboken)       Date:  2014-11       Impact factor: 4.794

7.  Performance of the UCLA Scleroderma Clinical Trials Consortium Gastrointestinal Tract 2.0 instrument as a clinical decision aid in the routine clinical care of patients with systemic sclerosis.

Authors:  Norina Zampatti; Alexandru Garaiman; Suzana Jordan; Rucsandra Dobrota; Mike Oliver Becker; Britta Maurer; Oliver Distler; Carina Mihai
Journal:  Arthritis Res Ther       Date:  2021-04-22       Impact factor: 5.156

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.